This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of amantadine
PDMED_AMANTADINE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
624 |
4. Check minimum number of events
Min. number of events
3
|
624 |
5. Include endpointsNone |
624 |
6. Filter based on genotype QC (FinnGen only) |
611 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Use of amantadine
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 611 | 397 | 214 |
| Unadjusted period prevalence (%) | 0.13 | 0.14 | 0.10 |
| Median age at first event (years) | 53.22 | 48.88 | 61.29 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 624
- Matched controls
- 6240
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BD01
ATC
selegiline; oral
107.0
307.7
193
26
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
114.6
307.7
168
20
G20
ICD-10 Finland
Parkinson disease
54.2
307.7
252
77
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
44.0
307.7
259
99
N04BB01
ATC
amantadine; oral
+∞
307.7
624
27
109
Kela drug reimbursment
Multiple sclerosis
152.4
307.7
212
21
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
60.4
307.7
256
71
G35
ICD-10 Finland
Multiple sclerosis
137.0
307.7
263
33
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
139.0
307.7
186
19
N04BD02
ATC
rasagiline; oral
139.8
280.9
141
13
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
108.8
276.9
143
17
L03AB07
ATC
interferon beta-1a; parenteral
144.7
253.9
127
11
193
Kela drug reimbursment
Rasagiline
148.3
240.5
120
10
N04BC04
ATC
ropinirole; oral
90.0
198.8
105
14
L03AX13
ATC
glatiramer acetate; parenteral
117.5
193.8
99
10
N87
ICPC
Parkinsonism
45.7
192.1
116
31
N86
ICPC
Multiple sclerosis
228.4
155.8
155
9
M03BX01
ATC
baclofen; systemic
27.0
154.3
110
49
N04BC05
ATC
pramipexole; oral
10.2
146.3
201
279
N03AE01
ATC
clonazepam; systemic
11.7
133.8
156
173
H46
ICD-10 Finland
Optic neuritis
40.4
126.3
78
22
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
65.8
117.4
65
11
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
8.3
106.9
167
264
G04BD09
ATC
trospium; oral
12.8
75.6
77
68
L03AB08
ATC
interferon beta-1b; parenteral
175.3
74.9
77
5
G04BD12
ATC
mirabegron; oral
5.3
71.6
182
451
N04BX02
ATC
entacapone; oral
137.5
69.5
73
6
G04BD04
ATC
oxybutynin; oral, transdermal
6.6
64.7
118
214
XA800
NOMESCO Finland
Neuropsychological investigation
8.6
64.4
89
119
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
14.8
62.1
57
42
XKD06
NOMESCO Finland
Physiologic investigation of micturition
9.4
60.0
76
91
N03AX12
ATC
[U] gabapentin; oral
4.0
53.0
205
686
164
Kela drug reimbursment
Fingolimod
192.7
51.8
53
*
N06BA07
ATC
modafinil; oral
147.5
51.7
54
*
SPAT1229
SPAT
Assessment of need for aid
5.2
48.1
112
252
N04AA02
ATC
biperiden; systemic
11.2
45.2
49
47
L04AA27
ATC
[U] fingolimod
242.0
44.5
45
*
N04BC09
ATC
rotigotine; transdermal
75.7
43.7
49
7
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
236.2
43.5
44
*
353
Kela drug reimbursment
Cladribine and fingolimod
161.3
43.4
45
*
G04BD07
ATC
tolterodine; oral
5.8
43.1
86
168
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
64.8
41.9
48
8
SPAT1215
SPAT
Assessment of need for medical rehabilitation
7.1
40.4
64
99
L04AA31
ATC
[U] teriflunomide
115.3
40.3
43
*
XKC03
NOMESCO Finland
Water cystometry
7.3
38.9
60
90
N06AB04
ATC
citalopram; systemic
3.1
35.8
208
871
J01EA01
ATC
trimethoprim; systemic
2.9
35.1
252
1183
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
130.9
35.1
37
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
8.0
34.8
49
66
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
42.6
32.5
40
10
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
13.5
32.5
31
24
UKC02
NOMESCO Finland
Cystoscopy
3.3
32.5
155
575
Z2445
NOMESCO Finland
Psychologist
6.3
32.4
57
98
G04BD08
ATC
solifenacin; oral
4.3
31.6
91
240
SPAT1231
SPAT
Assessment of adjustments needed in living environment
9.6
31.5
38
42
XKD00
NOMESCO Finland
Uroflowmetry
3.4
31.3
136
475
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.1
31.3
162
629
L28
ICPC
Limited function/disability (L)
3.0
31.1
176
719
G02CB01
ATC
bromocriptine; systemic
10.0
30.9
36
38
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.8
30.6
104
309
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
11.6
30.4
32
29
N04BC02
ATC
pergolide; oral
317.0
30.1
30
*
N28
ICPC
Limited function/disability (N)
10.8
30.0
33
32
R35
ICD-10 Finland
Polyuria
4.3
29.8
83
213
R1250
NOMESCO Finland
Evaluation of functional capability
7.3
29.6
45
66
TAB00
NOMESCO Finland
Lumbar puncture
4.9
28.5
66
146
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.0
28.4
154
611
L04AX07
ATC
dimethyl fumarate; oral
67.3
28.2
32
5
N29
ICPC
Neurological sympt/complt other
8.6
27.6
36
44
G04BD11
ATC
fesoterodine; oral
7.2
27.5
42
62
N02BF01
ATC
gabapentin; oral
3.8
27.3
93
276
N04BX04
ATC
opicapone; oral
101.3
26.9
29
*
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
30.8
26.6
35
12
A06AD11
ATC
lactulose; oral
2.9
26.5
151
614
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.9
26.1
85
244
R33
ICD-10 Finland
Retention of urine
3.8
25.4
85
249
A28
ICPC
Limited function/disability NOS
2.8
25.3
161
692
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
7.0
24.9
39
59
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
25.6
24.6
34
14
N03AX16
ATC
[U] pregabalin
2.5
24.4
204
1002
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.6
24.3
87
266
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.0
23.7
71
192
N06AX16
ATC
venlafaxine; oral
2.9
23.2
130
520
AEA00
NOMESCO Finland
Replacement of impulse generator of stimulation device in the nervous system
23.1
23.2
33
15
XKD03
NOMESCO Finland
Urethral pressure profilometry
6.3
23.2
40
67
N06DA03
ATC
rivastigmine; oral, transdermal
4.4
22.2
58
141
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
18.3
21.5
33
19
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
7.8
21.4
30
40
N30.9
ICD-10 Finland
Cystitis, unspecified
3.8
21.3
69
197
N05AH04
ATC
quetiapine; oral
2.6
21.1
146
650
N07XX09
ATC
[U] dimethyl fumarate
62.3
21.0
24
*
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.3
20.9
245
1381
N06AX11
ATC
mirtazapine; oral
2.2
20.6
262
1525
N06AA09
ATC
amitriptyline; systemic
3.0
20.4
100
370
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.5
20.4
75
233
SPAT1216
SPAT
Assessment of functional ability
2.6
20.4
139
613
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.4
20.3
80
260
N05CF01
ATC
zopiclone; oral
2.2
20.1
265
1562
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.0
20.0
59
157
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
59.6
20.0
23
*
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.3
19.7
220
1209
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.7
19.4
125
535
N05BA01
ATC
diazepam; systemic, rectal
2.7
18.8
120
510
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.8
18.8
104
411
R25.1
ICD-10 Finland
Tremor, unspecified
5.1
18.8
40
82
TKC20
NOMESCO Finland
Catheterisation of bladder
3.5
18.6
69
215
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.5
18.6
144
673
A06AC01
ATC
ispaghula (psylla seeds); oral
2.2
18.5
212
1173
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.7
18.3
61
177
N30.0
ICD-10 Finland
Acute cystitis
2.5
18.3
133
603
R5110, ,
SPAT
3.4
18.0
70
225
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
97.9
17.6
19
*
J01MA02
ATC
ciprofloxacin; systemic
2.1
17.5
278
1735
U04
ICPC
Incontinence urine
3.7
17.3
58
169
N39.4
ICD-10 Finland
Other specified urinary incontinence
2.8
16.8
92
360
N04BC01
ATC
bromocriptine; oral
174.5
16.6
17
*
S72.0
ICD-10 Finland
Fracture of neck of femur
4.0
16.4
48
127
Z3226
NOMESCO Finland
Physiotherapist
2.3
16.3
148
737
XCK00
NOMESCO Finland
Perimetry
3.4
16.2
63
202
L04AE01
ATC
fingolimod; oral
+∞
15.7
15
*
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
87.3
15.6
17
*
R4130
NOMESCO Finland
Speech therapy
5.1
15.6
33
67
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
6.6
15.5
25
39
N05BA04
ATC
oxazepam; oral
2.1
15.3
198
1134
R1260
NOMESCO Finland
Evaluation of communicative skills
6.0
15.0
27
47
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
5.2
14.9
31
62
2AB04, ,
NOMESCO Finland
32.6
14.9
19
6
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
58.1
14.8
17
*
N04BC06
ATC
cabergoline; oral
25.8
14.8
20
8
AA1AD
NOMESCO Finland
CT of head and brain
2.1
14.8
197
1139
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.0
14.7
68
242
K59.0
ICD-10 Finland
Constipation
3.3
14.5
56
179
H02AA02
ATC
fludrocortisone; oral
13.8
14.3
24
18
D21
ICPC
Swallowing problem
6.4
14.3
24
39
ZXM20
NOMESCO Finland
Intraoperative use of computerised tomography
12.3
14.2
25
21
U13
ICPC
Bladder symptom/complaint other
4.6
14.2
34
77
H02AB04
ATC
methylprednisolone; systemic
2.3
14.1
119
572
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.4
14.0
106
485
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.7
13.7
82
335
N03AF01
ATC
carbamazepine; oral, rectal
3.3
13.7
54
175
N04BX01
ATC
tolcapone; oral
+∞
13.6
13
*
N04BC07
ATC
apomorphine; parenteral
+∞
13.6
13
*
34099
ICD-8 Finland
Multiple sclerosis
143.0
13.5
14
*
N05CD07
ATC
temazepam; oral
2.4
13.5
104
480
C07AA05
ATC
propranolol; systemic
2.1
13.4
154
837
TKC22
NOMESCO Finland
Catheterisation instruction
5.5
13.3
26
49
M03BX02
ATC
tizanidine; oral
1.9
13.0
401
3031
L04AK02
ATC
teriflunomide; oral
51.1
12.9
15
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.1
12.9
137
723
NFB20
NOMESCO Finland
Primary partial prosthetic replacement of hip joint using cement, other or unspecified
4.7
12.7
30
67
J01CA08
ATC
pivmecillinam; oral
1.8
12.5
293
2021
N06AB10
ATC
escitalopram; oral
2.1
12.3
145
793
U02
ICPC
Urinary frequency/urgency
2.3
12.3
110
540
H02AB07
ATC
prednisone; oral
2.3
12.1
108
530
L04AX01
ATC
azathioprine; systemic
3.9
12.0
36
97
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
66.2
11.6
13
*
359
Kela drug reimbursment
Mirabegroni
15.4
11.4
18
12
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
15.4
11.4
18
12
N06AX18
ATC
reboxetine; oral
10.8
11.3
21
20
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
9.9
11.3
22
23
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.2
11.2
112
575
I95.1
ICD-10 Finland
Orthostatic hypotension
3.6
11.0
36
103
U07
ICPC
Urine symptom/complaint other
2.7
11.0
60
234
R4110, ,
SPAT
2.5
10.9
71
302
H53.2
ICD-10 Finland
Diplopia
3.6
10.9
36
104
J01XE01
ATC
nitrofurantoin; oral
4.7
10.8
25
55
G04AC01, ,
ATC
3.7
10.8
34
95
J01MA06
ATC
norfloxacin; oral
2.1
10.7
108
556
SPAT1167
SPAT
Insertion of urinary catheter
4.4
10.7
27
64
R53
ICD-10 Finland
Malaise and fatigue
1.9
10.6
169
1022
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
4.6
10.6
25
56
4AA23, ,
NOMESCO Finland
111.8
10.4
11
*
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
111.8
10.4
11
*
R4110
NOMESCO Finland
Physiotherapy
1.8
10.4
188
1183
ZX120
NOMESCO Finland
Intravenous
2.4
10.3
72
316
SPAT1262
SPAT
Handing over of treatment supplies
2.0
10.3
120
651
H47.2
ICD-10 Finland
Optic atrophy
23.8
10.3
14
6
XF606
NOMESCO Finland
Ortostatic test
13.4
10.2
17
13
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.4
10.2
76
344
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.0
10.2
47
167
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
1.9
10.1
174
1078
J01XX05
ATC
methenamine; oral
8.3
9.9
21
26
A07DA03
ATC
loperamide; oral
3.6
9.9
33
96
G04CA02
ATC
tamsulosin; oral
1.9
9.9
136
782
S97
ICPC
Chronic ulcer skin
2.7
9.8
54
211
L89
ICD-10 Finland
Decubitus ulcer and pressure area
4.8
9.8
22
47
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
9.8
9.8
19
20
J01MA01
ATC
ofloxacin; systemic
2.4
9.8
70
311
N06AX21
ATC
duloxetine; oral
2.2
9.8
88
432
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
3.9
9.7
29
78
L03AB13
ATC
peginterferon beta-1a; parenteral
101.5
9.4
10
*
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
22.1
9.4
13
6
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.3
9.4
79
377
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
7.5
9.3
21
29
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.2
9.3
88
441
R4120
NOMESCO Finland
Occupational therapy
2.6
9.2
53
212
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
2.6
9.2
56
231
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
2.9
9.1
43
155
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
15.9
9.1
14
9
K03.66
ICD-10 Finland
Tooth plaque
2.6
9.1
52
208
Z93.5
ICD-10 Finland
Cystostomy status
37.3
9.0
11
*
R5130, ,
SPAT
37.3
9.0
11
*
Z3231
NOMESCO Finland
Registered nurse
1.8
9.0
179
1153
G04BDXX, ,
ATC
24.4
8.9
12
5
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
3.3
8.9
34
108
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.2
8.9
82
406
U71
ICPC
Cystitis/urinary infection other
2.6
8.8
54
223
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
2.6
8.8
51
205
W19
ICD-10 Finland
Unspecified fall
2.2
8.7
73
347
N19
ICPC
Speech disorder
7.8
8.7
19
25
AAW01
NOMESCO Finland
Implantation of intracranial stimulation device
50.7
8.7
10
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.7
8.7
230
1601
N05BA12
ATC
alprazolam; oral
2.2
8.6
74
356
N03AF02
ATC
oxcarbazepine; oral
3.4
8.6
31
95
N03AX09
ATC
lamotrigine; oral
3.0
8.5
37
127
N07AA03
ATC
distigmine; systemic
27.9
8.5
11
*
YX8AD
NOMESCO Finland
Stereotactic CT examination for dose design of radiotherapy
27.9
8.5
11
*
M48.0
ICD-10 Finland
Spinal stenosis
2.1
8.5
91
477
XF400
NOMESCO Finland
ECG with 12 standard connections
2.0
8.5
107
595
S01.0
ICD-10 Finland
Open wound of scalp
2.4
8.4
60
267
N04AA01
ATC
trihexyphenidyl; oral
+∞
8.3
8
*
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
11.9
8.1
14
12
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
4.2
8.1
21
51
N02AX02
ATC
tramadol; systemic, rectal
1.6
8.0
272
2006
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.0
8.0
90
480
X59
ICD-10 Finland
Exposure to unspecified factor
1.9
7.8
118
697
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
6.0
7.7
20
34
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
2.5
7.6
50
214
ABC26
NOMESCO Finland
Open discectomy of lumbar spine
4.5
7.5
18
41
K59.09
ICD-10 Finland
Constipation, unspecified
2.4
7.4
50
216
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
81.0
7.4
8
*
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
7.3
7
*
3419X
ICD-9 Finland
Other demyelinating diseases of central nervous system, Demyelinating disease of central nervous system, unspecified
+∞
7.3
7
*
AA5QN, ,
NOMESCO Finland
+∞
7.3
7
*
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
1.9
7.3
98
556
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
4.4
7.3
18
42
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
16.0
7.2
11
7
H53.1
ICD-10 Finland
Subjective visual disturbances
2.4
7.2
48
206
A02BA02
ATC
ranitidine; systemic
1.8
7.2
134
839
Z01.8
ICD-10 Finland
Other specified special examinations
1.7
7.2
139
880
WX110
NOMESCO Finland
Infiltration anesthesia
1.6
7.2
415
3443
G04BD
ATC
Drugs for urinary frequency and incontinence
20.3
7.1
10
5
N05AB04
ATC
prochlorperazine; systemic, rectal
3.8
7.1
21
56
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
6.1
7.1
18
30
ND1BA
NOMESCO Finland
Wrist extensive X-ray examination
3.8
7.0
21
57
M01AG02
ATC
tolfenamic acid; oral, rectal
1.8
6.9
105
618
N05CF02
ATC
zolpidem; oral
1.8
6.9
118
721
N02AA05
ATC
oxycodone; systemic
1.8
6.8
118
723
Z43.5
ICD-10 Finland
Attention to cystostomy
11.1
6.8
12
11
N02AC04
ATC
dextropropoxyphene; oral
2.9
6.8
31
110
36703
ICD-8 Finland
Inflammation of optic nerve and retina, Neuritis optica, retrobulbaris
40.5
6.8
8
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
7.3
6.7
15
21
K02.1
ICD-10 Finland
Caries of dentine
1.6
6.7
332
2638
A02BC02
ATC
pantoprazole; systemic
1.6
6.7
419
3509
R03CC02
ATC
salbutamol; systemic
3.4
6.6
23
69
3AX01, ,
NOMESCO Finland
12.4
6.6
11
9
R06AE07
ATC
cetirizine; oral
1.6
6.6
258
1944
SPAT1296
SPAT
Other function in accordance with occupational therapy nomenclature
8.8
6.6
13
15
SPAT1172
SPAT
Guidance concerning hydration
3.9
6.6
19
50
Z3229
NOMESCO Finland
Other healthcare associate professional
2.2
6.5
58
283
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
7.5
6.4
14
19
SPAT1255
SPAT
Intravenous administration of medicine
2.4
6.4
44
192
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
3.0
6.4
28
97
F05.9
ICD-10 Finland
Delirium, unspecified
4.1
6.4
17
42
J01DB01
ATC
cefalexin; oral
1.7
6.4
494
4330
N06AX12
ATC
bupropion; oral
2.4
6.3
42
181
L04AG12
ATC
ofatumumab; parenteral
+∞
6.3
6
*
R03CA02
ATC
ephedrine; oral
27.0
6.2
8
*
A99
ICPC
Disease/condition unspecnature/site
2.1
6.2
59
295
L17
ICPC
Foot/toe symptom/complaint
1.6
6.2
175
1219
A04
ICPC
Weakness/tiredness general
1.8
6.2
89
515
M41.9
ICD-10 Finland
Scoliosis, unspecified
5.4
6.2
17
32
Z10.0
ICD-10 Finland
Occupational health examination
0.2
6.2
*
251
SPAT1234
SPAT
Support of social functional capacity
2.5
6.2
38
158
SPAT1254
SPAT
Administration of medicine
1.8
6.1
90
524
SFA20
NOMESCO Finland
Two-surface restoration
1.5
6.1
334
2692
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
8.7
6.1
12
14
A02BX02
ATC
sucralfate; oral
2.6
6.1
33
129
H03AA01
ATC
levothyroxine sodium; systemic
1.6
6.0
151
1021
G04BD01
ATC
emepronium; systemic
5.6
6.0
16
29
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
5
56.30
23.23
2.0
3.6
—
—
—
0
0
35
51
7.21
23.13
1.2
1.2
—
—
—
0
0
265
1511
2.31
22.29
5.4
3.1
40.94
57.55
e6/l
0.30
213
1159
298
1794
2.27
21.90
5.3
3.1
—
—
—
0
0
362
2370
2.26
21.54
10.2
5.6
26.58
27.62
%
1.04
342
2228
359
2343
2.25
21.52
9.6
5.3
59.44
57.41
%
2.49
339
2200
355
2307
2.25
21.50
10.1
5.4
2.89
2.82
%
0.26
331
2159
241
1381
2.21
19.43
5.0
3.0
0.26
0.43
e6/l
1.13
193
1041
196
1058
2.24
18.08
4.3
2.5
4.61
6.07
e6/l
0.87
175
952
23
32
7.42
15.77
1.1
1.0
—
—
—
0
0
394
2860
2.02
15.67
10.7
8.8
4.07
4.12
e9/l
0.16
362
2515
24
37
6.71
15.02
1.0
1.1
46.33
41.93
mg/l
0.14
15
31
37
87
4.46
14.74
3.8
3.1
3.93
4.59
e9/l
0.88
37
87
18
6
30.82
13.94
1.1
1.0
—
—
—
0
0
350
2504
1.91
13.77
6.5
3.7
0.00
0.01
estimate
0.50
70
437
146
775
2.15
13.56
4.3
2.8
4.49
2.53
e6/l
0.92
84
421
37
93
4.17
13.54
3.9
3.5
60.43
59.58
%
0.13
37
93
346
2477
1.89
13.47
6.5
3.7
0.00
0.00
estimate
0.50
78
487
431
3316
1.97
13.45
9.7
4.5
516.89
2546.90
e6/l
—
9
60
23
19
12.52
13.19
1.7
1.3
56.17
102.32
nmol/l
0.70
12
13
344
2478
1.87
12.93
8.9
4.9
0.00
0.00
estimate
0.50
74
454
305
2129
1.85
12.56
2.5
2.2
92.21
77.82
nmol/l
9.76
267
1901
148
827
2.04
11.84
4.2
2.6
1.20
1.08
e6/l
0.25
88
472
24
57
4.34
9.45
1.0
1.1
—
—
—
0
0
24
59
4.19
9.05
1.0
1.1
—
—
—
0
0
26
69
3.89
8.87
2.1
2.5
106.73
105.77
mmol/l
0.36
26
69
26
69
3.89
8.87
2.1
2.5
4.06
4.02
mmol/l
0.18
26
69
131
779
1.86
8.48
1.7
1.9
—
—
—
0
0
20
32
6.42
8.07
2.5
1.8
—
—
—
0
0
322
2493
1.60
7.67
6.0
6.2
1.22
1.22
mmol/l
0.06
270
2120
217
1528
1.64
7.62
2.5
2.0
180.05
191.01
u/l
0.12
206
1434
20
49
4.18
7.59
1.0
1.0
—
—
—
0
0
13
12
11.03
7.32
7.2
1.3
—
—
—
0
0
31
108
2.97
7.00
1.2
1.2
76.45
157.34
e6/l
0.53
22
82
31
108
2.97
7.00
1.1
1.2
5.32
13.25
e6/l
0.57
22
80
32
114
2.90
6.95
2.8
1.9
16274.11
1051.37
u/l
—
10
37
37
144
2.67
6.82
1.6
1.6
70.09
0.14
iu/ml
—
5
25
258
1934
1.57
6.80
7.3
3.8
—
—
—
0
0
299
2330
1.54
6.56
8.5
13.4
1.11
1.23
inr
2.45
93
658
271
2069
1.55
6.51
2.3
2.0
93.85
95.94
pmol/l
0.31
150
1050
358
2925
1.53
6.16
5.5
4.4
6.41
6.71
mmol/l
2.45
345
2733
424
4795
0.64
6.05
3.9
3.9
1.23
1.28
mmol/l
0.80
370
4380
444
4961
0.64
5.82
4.3
4.4
1.51
1.50
mmol/l
0.15
385
4561
288
2272
1.50
5.70
6.3
5.5
1.22
1.22
mmol/l
0.04
264
2064
169
1192
1.57
5.62
1.8
1.5
21.39
20.91
nmol/l
0.14
138
1010
449
3892
1.55
5.56
6.9
7.2
80.94
78.48
u/l
0.46
412
3646
461
5094
0.64
5.48
4.6
5.0
2.70
2.78
mmol/l
0.96
401
4684
450
4988
0.65
5.25
4.2
4.4
4.62
4.72
mmol/l
1.03
393
4608
138
959
1.56
4.82
1.8
1.7
1009.28
1209.44
nmol/l
1.89
100
706
51
267
1.99
4.79
4.6
2.8
0.11
0.18
e6/l
0.70
51
260
14
31
4.60
4.58
1.0
1.1
1.25
1.14
u/l
—
6
17
10
15
6.75
4.48
1.2
1.1
2060.80
1707.47
miu/ml
—
10
15
55
305
1.88
4.39
1.4
1.4
—
—
—
0
0
86
546
1.67
4.33
1.6
1.8
—
—
—
0
0
38
188
2.09
4.18
1.9
1.9
—
—
—
0
0
36
175
2.12
4.14
1.8
1.7
—
—
—
0
0
52
289
1.87
4.13
1.6
1.8
—
—
—
0
0
85
550
1.63
3.98
1.6
1.9
—
—
—
0
0
315
2655
1.38
3.79
4.7
5.9
9.48
10.95
umol/l
3.30
295
2522
279
2315
1.37
3.66
2.5
2.5
—
—
—
0
0
263
2164
1.37
3.63
3.7
4.3
35.36
35.58
g/l
0.24
236
2013
7
9
7.85
3.56
1.6
2.0
14.06
18.81
umol/l
—
7
9
20
436
0.44
3.39
1.8
1.7
—
—
—
0
0
53
319
1.72
3.27
1.4
1.3
—
44.75
—
0
25
154
1177
1.41
3.25
2.1
2.2
—
—
—
0
0
172
1340
1.39
3.25
7.8
4.0
0.00
0.00
estimate
0.50
69
444
10
24
4.22
3.20
2.8
2.3
—
—
—
0
0
238
1959
1.35
3.17
4.7
3.6
32.21
52.61
ng/l
0.55
190
1384
40
226
1.82
3.06
9.1
2.2
0.73
0.64
%
1.19
40
226
76
513
1.55
3.00
4.9
3.3
—
—
—
0
0
25
124
2.06
2.80
1.5
1.7
5.59
5.57
iu/l
—
7
38
48
295
1.68
2.78
3.3
3.6
2.15
1.99
mmol/l
0.16
43
226
417
3768
1.32
2.72
3.7
4.1
10.99
12.36
mm/h
1.43
371
3462
22
418
0.51
2.57
2.0
2.7
63.00
64.45
ml/min/173m2
—
7
190
20
100
2.03
2.23
2.1
1.6
—
—
—
0
0
11
252
0.43
2.18
1.1
1.3
—
—
—
0
0
92
689
1.39
2.17
1.6
2.2
2.41
2.32
g/l
0.66
80
635
7
19
3.71
2.15
2.0
1.7
67.20
59.25
ug/l
—
7
19
529
5006
1.37
2.15
19.4
13.9
25.99
22.91
mg/l
1.09
436
3938
121
1510
0.75
2.08
3.2
3.1
8.12
7.24
mmol/l
1.09
96
1254
195
1639
1.28
2.08
3.6
3.0
28.74
30.20
u/l
0.37
186
1558
99
757
1.37
2.07
1.8
2.2
11.86
13.00
umol/l
0.87
86
699
19
97
1.99
2.02
1.2
1.4
—
—
—
0
0
19
97
1.99
2.02
1.2
1.4
—
—
—
0
0
61
432
1.46
1.97
7.9
3.1
2.59
2.09
mmol/l
0.73
51
348
11
45
2.47
1.94
2.1
2.3
—
—
—
0
0
544
5190
1.38
1.93
20.7
16.0
3.92
3.97
mmol/l
4.37
532
5030
58
410
1.46
1.89
3.3
3.7
1.22
1.23
mmol/l
0.38
50
358
464
4336
1.27
1.89
23.2
16.5
14.86
15.00
%
0.19
457
4262
542
5173
1.36
1.87
20.9
15.9
139.87
139.68
mmol/l
0.99
534
5022
133
1079
1.30
1.85
1.3
1.2
0.78
1.68
u/ml
1.15
25
286
21
115
1.85
1.85
1.2
1.2
—
—
—
0
0
21
115
1.85
1.85
1.6
1.7
—
—
—
0
0
5
12
4.19
1.82
1.2
1.7
—
—
—
0
0
421
3912
1.23
1.68
4.6
4.0
15.16
14.71
pmol/l
2.68
377
3549
18
97
1.88
1.67
3.3
2.4
16.07
15.61
%
0.20
11
48
492
4653
1.27
1.67
5.7
4.8
1.80
2.18
mu/l
0.80
453
4238
175
1488
1.24
1.65
2.5
3.1
1085.06
1287.19
ng/l
0.43
153
1257
7
25
2.82
1.65
1.1
1.4
—
—
—
0
0
148
1240
1.25
1.59
2.6
2.0
3.47
3.15
mg/l
0.55
126
1060
83
645
1.33
1.58
1.7
2.3
19.54
22.55
%
1.26
70
557
64
840
0.73
1.55
1.7
1.5
—
—
—
0
0
5
126
0.39
1.51
1.2
1.5
—
—
—
0
0
9
39
2.33
1.43
1.3
1.8
—
—
—
0
0
39
543
0.70
1.36
3.6
4.1
3.23
28.69
ug/l
1.07
33
449
0
38
0.00
1.34
0.0
2.3
—
—
—
0
0
0
39
0.00
1.34
0.0
1.1
—
—
—
0
0
469
4907
0.82
1.30
4.2
4.6
5.72
5.93
mmol/l
4.81
418
4466
5
18
2.79
1.28
1.8
3.0
34220.00
35772.50
ug/l
—
5
18
15
84
1.81
1.28
1.4
1.3
—
—
—
0
0
498
4761
1.23
1.27
17.2
13.0
84.96
79.92
ml/min/173m2
6.64
443
3910
75
595
1.30
1.26
3.6
4.7
1.03
1.02
mmol/l
0.20
65
535
129
1092
1.23
1.26
1.8
1.7
423.27
24833403.06
pmol/l
1.30
106
898
21
135
1.57
1.12
2.1
1.5
—
—
—
0
0
354
3303
1.17
1.12
3.8
3.0
47.63
46.69
u/l
0.06
316
3087
27
185
1.48
1.10
1.4
2.0
—
—
—
0
0
179
1586
1.18
1.08
2.3
2.4
51.26
58.93
u/l
1.43
163
1468
7
33
2.13
1.06
1.1
1.5
3.14
3.04
u/field
—
7
24
100
841
1.23
1.05
1.5
1.4
—
—
—
0
0
61
484
1.29
1.05
2.4
1.8
352.67
377.90
nmol/l
0.47
55
441
8
149
0.53
1.04
1.5
1.2
—
—
—
0
0
5
22
2.28
1.03
1.0
1.0
—
—
—
0
0
13
76
1.73
0.99
1.3
1.6
—
—
—
0
0
127
1101
1.19
0.99
6.4
4.0
1.02
1.02
kg/l
0.09
27
137
240
2191
1.16
0.98
2.7
2.7
123.35
117.10
ug/l
0.18
218
2018
5
23
2.18
0.98
1.6
2.0
—
—
—
0
0
5
23
2.18
0.98
1.2
1.3
—
—
—
0
0
86
1019
0.82
0.96
4.2
4.4
21.34
21.17
%
0.04
45
476
11
62
1.79
0.94
2.1
2.0
88.30
89.82
%
0.30
11
62
61
748
0.80
0.93
3.2
2.9
0.72
0.77
ug/l
0.23
43
489
45
349
1.31
0.93
2.0
1.5
—
—
—
0
0
6
28
2.15
0.91
1.5
1.9
—
—
—
0
0
9
153
0.58
0.89
1.1
1.1
—
—
—
0
0
451
4684
0.87
0.86
5.3
5.7
38.99
39.87
mmol/mol
1.28
398
4344
56
454
1.26
0.84
1.9
2.3
28.26
30.85
u/l
0.44
46
382
6
32
1.88
0.82
1.5
1.5
7.17
9.50
u/l
—
6
26
18
122
1.49
0.81
1.2
1.7
—
—
—
0
0
135
1514
0.86
0.80
3.8
3.8
3.90
7.42
mg/mmol
2.25
89
929
0
25
0.00
0.79
0.0
1.3
—
—
—
0
0
23
165
1.41
0.78
1.4
1.6
—
—
—
0
0
0
26
0.00
0.78
0.0
1.2
—
—
—
0
0
75
637
1.20
0.75
4.2
4.5
32.18
31.76
%
0.11
51
428
5
24
2.09
0.74
1.6
1.9
—
—
—
0
0
121
1358
0.86
0.73
1.6
1.6
1.36
1.37
mmol/l
0.02
92
1135
9
56
1.62
0.72
1.3
1.7
—
—
—
0
0
49
400
1.24
0.72
1.8
2.5
66.83
66.94
g/l
0.05
39
363
5
26
1.93
0.70
1.8
1.7
—
—
—
0
0
5
26
1.93
0.70
1.8
1.7
—
—
—
0
0
322
3046
1.12
0.70
3.0
3.0
—
—
—
0
0
17
118
1.45
0.70
1.3
1.3
—
—
—
0
0
79
910
0.85
0.67
1.4
1.3
13.05
35.11
iu/ml
5.50
13
303
7
43
1.63
0.67
1.3
1.1
1.42
1.42
nmol/l
—
7
37
18
128
1.42
0.66
1.2
1.7
—
—
—
0
0
5
28
1.79
0.66
1.0
1.1
—
—
—
0
0
106
941
1.15
0.64
4.5
3.8
111.89
317.59
ng/l
1.35
80
727
10
153
0.65
0.63
1.1
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
3.6
—
207.67
—
0
21
189
1750
1.11
0.59
2.5
3.3
2.35
2.36
mmol/l
0.54
156
1541
13
89
1.47
0.58
1.3
1.6
—
—
—
0
0
10
66
1.52
0.53
1.3
1.7
—
—
—
0
0
9
65
1.39
0.50
1.1
1.1
—
—
—
0
0
115
1259
0.89
0.49
1.9
2.5
304.83
6636.92
umol/l
5.05
96
1099
19
145
1.32
0.49
1.5
1.4
317.57
302.73
ug/g
0.11
12
84
77
860
0.88
0.46
1.4
1.3
1.09
9.62
u/ml
3.96
20
341
106
966
1.12
0.45
2.4
2.8
2.46
2.45
mmol/l
0.53
93
843
12
164
0.73
0.45
2.3
2.9
—
—
—
0
0
7
51
1.38
0.44
1.3
1.5
19.88
16.87
ug/l
—
7
51
0
16
0.00
0.41
0.0
1.0
—
25.81
—
0
16
5
34
1.47
0.40
1.2
1.5
69.80
76.44
umol/l
—
5
34
8
61
1.32
0.39
1.1
1.3
—
—
—
0
0
25
206
1.22
0.38
1.6
2.0
1.37
1.53
g/l
0.53
20
179
5
36
1.39
0.38
1.8
1.1
—
—
—
0
0
5
36
1.39
0.38
1.8
1.1
—
—
—
0
0
9
68
1.33
0.37
1.1
1.4
—
—
—
0
0
8
114
0.70
0.37
1.3
1.4
—
—
—
0
0
5
37
1.35
0.37
1.8
1.1
—
—
—
0
0
5
37
1.35
0.37
1.8
1.1
—
—
—
0
0
5
37
1.35
0.37
1.8
1.1
—
—
—
0
0
9
70
1.29
0.36
1.1
1.4
—
—
—
0
0
9
70
1.29
0.36
1.1
1.4
—
—
—
0
0
9
70
1.29
0.36
1.1
1.4
—
—
—
0
0
9
70
1.29
0.36
1.3
1.6
—
—
—
0
0
9
70
1.29
0.36
1.1
1.4
—
—
—
0
0
9
71
1.27
0.36
1.1
1.4
—
—
—
0
0
12
90
1.34
0.36
1.3
1.7
—
—
—
0
0
44
386
1.15
0.35
3.4
3.3
69.20
77.83
ng/l
0.67
30
339
10
73
1.38
0.34
1.3
1.6
—
—
—
0
0
49
551
0.88
0.34
1.4
1.7
1.44
1.45
%
0.09
43
480
19
154
1.24
0.34
1.5
1.7
—
—
—
0
0
13
100
1.31
0.33
1.7
1.5
—
—
—
0
0
15
118
1.28
0.33
1.1
1.4
—
—
—
0
0
36
413
0.86
0.33
1.8
1.8
—
—
—
0
0
11
144
0.76
0.33
2.4
2.3
12.99
12.29
mg/l
0.08
11
131
6
46
1.31
0.33
1.0
1.2
—
70.43
—
0
7
25
211
1.19
0.32
1.6
1.7
—
—
—
0
0
540
5330
1.10
0.31
13.4
10.2
22.58
24.94
u/l
3.33
507
5136
120
1124
1.08
0.31
2.1
1.6
1.29
1.15
mg/l
0.25
98
881
18
148
1.22
0.29
1.3
1.2
—
—
—
0
0
12
151
0.79
0.28
2.7
3.4
—
2.18
—
0
17
8
64
1.25
0.27
3.0
3.1
22.21
63.94
u/ml
—
8
64
61
559
1.10
0.26
4.6
6.9
0.16
1.42
mmol/l
1.14
48
448
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
1.25
—
0
12
0
12
0.00
0.21
0.0
2.1
—
2.78
—
0
5
5
43
1.16
0.21
1.0
1.5
—
241.43
—
0
7
85
802
1.07
0.20
2.8
3.1
0.82
0.82
mmol/l
0.21
77
749
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
7
58
1.21
0.18
1.0
1.1
1.31
1.47
g/l
—
7
51
61
572
1.07
0.18
2.1
2.4
8.80
7.54
umol/l
0.27
51
498
47
436
1.08
0.17
10.4
6.0
1.34
1.36
mmol/l
0.06
47
420
7
61
1.15
0.17
1.0
1.4
—
—
—
0
0
7
61
1.15
0.17
1.0
1.4
—
—
—
0
0
5
69
0.72
0.17
1.0
2.9
—
940.88
—
0
8
20
225
0.89
0.16
1.1
1.0
—
—
—
0
0
14
120
1.17
0.16
1.3
1.1
—
—
—
0
0
34
370
0.91
0.16
1.7
1.7
—
—
—
0
0
13
111
1.17
0.16
1.1
1.2
—
9.47
—
0
9
18
201
0.89
0.13
1.7
1.9
1.46
3.46
mg/l
1.93
13
154
34
361
0.94
0.10
1.3
1.2
66.16
162.55
iu/ml
2.85
13
148
10
113
0.88
0.08
1.7
4.0
33.40
28.25
mg/l
—
5
68
5
60
0.83
0.08
1.2
1.7
—
—
—
0
0
6
75
0.80
0.07
1.7
1.5
—
—
—
0
0
19
176
1.08
0.07
1.4
1.4
—
—
—
0
0
9
86
1.05
0.07
1.0
1.2
—
—
—
0
0
13
119
1.09
0.06
1.1
1.2
—
—
—
0
0
16
149
1.08
0.05
1.8
1.6
—
—
—
0
0
15
140
1.07
0.04
1.2
1.2
—
2.78
—
0
18
16
151
1.06
0.03
1.4
1.2
—
18.30
—
0
10
127
1284
0.99
0.03
5.0
4.9
2.51
2.48
ug/l
0.02
111
1137
42
426
0.98
0.00
1.9
2.4
4.61
7.07
ug/l
1.10
33
375
62
626
0.99
0.00
5.5
6.8
—
—
—
0
0
18
176
1.02
0.00
1.6
2.0
—
—
—
0
0
13
127
1.02
0.00
1.2
1.4
—
—
—
0
0
555
5546
1.01
0.00
29.7
20.5
39.30
39.89
%
1.12
518
5193
555
5553
1.00
0.00
29.7
20.6
132.98
134.13
g/l
1.11
550
5460
18
179
1.01
0.00
1.5
1.5
—
—
—
0
0
555
5551
1.00
0.00
29.4
20.5
4.40
4.45
e12/l
1.67
540
5392
555
5549
1.00
0.00
29.4
20.5
260.08
252.11
e9/l
2.31
545
5409
7
70
1.00
0.00
1.1
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
9
90
1.00
-0.00
1.1
1.6
—
—
—
0
0
8
81
0.99
-0.00
1.0
1.1
—
17.18
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
54
0.93
-0.00
1.2
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
6
60
1.00
-0.00
3.8
3.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
7
75
0.93
-0.00
1.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
9
90
1.00
-0.00
1.1
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_AMANTADINE – Use of amantadine
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).